ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 209 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2023. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $86,000 | -18.1% | 15,578 | 0.0% | 0.00% | – |
Q2 2023 | $105,000 | -46.4% | 15,578 | -29.8% | 0.00% | – |
Q1 2023 | $196,000 | -8.0% | 22,178 | -19.9% | 0.00% | – |
Q4 2022 | $213,000 | +8.1% | 27,703 | 0.0% | 0.00% | -100.0% |
Q3 2022 | $197,000 | -12.8% | 27,703 | -0.4% | 0.00% | 0.0% |
Q2 2022 | $226,000 | +41.2% | 27,816 | +144.1% | 0.00% | – |
Q1 2022 | $160,000 | -61.7% | 11,397 | -7.4% | 0.00% | -100.0% |
Q3 2021 | $418,000 | -27.9% | 12,311 | -13.3% | 0.00% | -50.0% |
Q2 2021 | $580,000 | -8.1% | 14,200 | -9.4% | 0.00% | 0.0% |
Q1 2021 | $631,000 | -62.8% | 15,670 | -45.4% | 0.00% | -71.4% |
Q4 2020 | $1,698,000 | +68.6% | 28,712 | +38.7% | 0.01% | +40.0% |
Q3 2020 | $1,007,000 | +60.6% | 20,700 | +59.8% | 0.01% | +66.7% |
Q2 2020 | $627,000 | -17.1% | 12,950 | -52.4% | 0.00% | -40.0% |
Q1 2020 | $756,000 | -55.9% | 27,200 | -52.6% | 0.01% | -50.0% |
Q4 2019 | $1,716,000 | – | 57,375 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
Triatomic Management LP | 121,166 | $813,024 | 0.83% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |